Stopping and Restarting a GLP-1 Drug Repeatedly May Worsen Metabolic Health in Aging Obese Mice

Aged obese UM-HET3 mice (a genetically diverse mouse strain) were divided into three groups: one receiving no liraglutide (OFF), one undergoing three cycles of treatment followed by withdrawal (ON/OFF), and one on continuous liraglutide treatment (ON). Researchers tracked body weight, food intake, body composition (fat vs. lean mass), leptin levels, and metabolic health markers across the treatment cycles.

GLP-1 receptor agonists like liraglutide and semaglutide are among the most prescribed weight-loss drugs today. Many patients stop and restart these medications due to cost, side effects, or supply issues. This study provides the first evidence in aged animals that this yo-yo pattern may not simply return you to baseline — it could actively worsen metabolic health by driving up leptin, expanding visceral fat, and eroding muscle mass, which is especially dangerous in older adults already at risk for sarcopenia.

As millions of people worldwide use GLP-1 agonists for obesity and diabetes, questions about what happens when treatment is interrupted are increasingly urgent. This study adds to growing evidence that these drugs may need to be taken continuously to maintain benefits, and that cycling on and off could create a worse metabolic profile than never starting treatment — particularly for aging populations where muscle preservation is critical.

This was conducted in mice, not humans, so the findings may not directly translate to human patients. The UM-HET3 strain, while genetically diverse, does not fully replicate human metabolic complexity. The study did not report specific numerical values for leptin levels, body weight changes, or lean mass loss in the abstract. Long-term survival outcomes were not assessed.